Skip to main content
Quest Diagnostics

Budget Impact of Circulating Tumor DNA Testing for Colon Cancer to Healthcare Insurers

AMCP 2025

Academy of Managed Care Primary

Houson, TX, Mar 31-Apr 3, 2025

Poster presentation: Budget Impact of Circulating Tumor DNA Testing for Colon Cancer to Healthcare Insurers

Authors: Li Y, Heer AK, Sloane HS, Edelstein DL

Specialty: Oncology

Related content

Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Test FAQ
Haystack MRD Testing
On-Demand Webinar
Early Detection Better Protection - Colorectal Cancer Screening in the Workplace: A Panel Discussion
Conference Presentation
Analytical Validation of the Haystack MRD Assay for the detection of extremely low ctDNA in Solid Tumor Patients
Test FAQ
Hereditary Colorectal Cancer Panel
Publication
Prediction of Future Medical Costs by Modifiable Measures of Health
Conference Presentation
Cost effectiveness of population-level preventative genetic screening for underdiagnosed hereditary conditions and implications for implementation by health systems

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.